Tests DJI136 cell therapy in adults with extensive-stage small cell lung cancer
Tests DJI136, an immune cell therapy, in adults with advanced small cell lung cancer.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Barcelona, Madrid, and Valencia, SpainSee the 4 sitesAlso in 1 other country, 3 sites
- Trial code
- EU 2025-523276-23-00
- U1111-1332-6878
- Registry title
- A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 25 people, planned
- Started
- 9 Oct 2026
- Expected to end
- 3 Mar 2031
- Type of study
- Interventional
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small cell lung cancer whose disease got worse after earlier chemotherapy. It tests DJI136, a CAR-T cell therapy aimed at DLL3.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Extensive-stage small cell lung cancer (ES-SCLC), confirmed by a tissue or cell test, with at least one lesion that can be measured. The disease must have got worse after earlier chemotherapy. Phase I Part A: after one or more chemotherapy regimens. Phase II Group A: after one regimen of platinum chemotherapy with a PD-L1 inhibitor. Exceptions apply if the patient could not receive such therapy.
- Earlier treatment
- Must have had platinum-based chemotherapy together with a PD-L1 inhibitor, unless the doctor judges the patient could not receive it. Earlier DLL3-targeted therapy is allowed in Phase I Part A and not allowed in Phase II Group A. Earlier genetically modified cell therapy, including DLL3-targeted CAR-T, is not allowed.
- Biomarker or test result
- Archival tumor tissue taken within 6 months before screening, or willingness to have a new tumor biopsy.
Main reasons for not taking part
- Earlier genetically modified cell therapy, including DLL3-targeted CAR-T
- Unstable or symptomatic brain metastases or carcinomatous meningitis
- Active serious infections, including hepatitis B/C and HIV
- Earlier solid organ transplant or donor stem cell transplant
- Pregnant or nursing women
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Phase I Part A: Patients with ES-SCLC and disease progression after one or more chemotherapy regimens (that included a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor) according to the local SOC (2L+), unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, according to the investigator's judgement. Prior DLL3 (Delta-like ligand 3) targeted therapy is allowed
- Phase II Group A: Patients with ES-SCLC and disease progression after one chemotherapy regimen with a platinum-based doublet chemotherapy in combination with a PD-L1 inhibitor according to the local - SOC (2L), unless the patient was ineligible to receive such therapies or was not a candidate for any available standard therapy, according to the investigator's judgement. Prior DLL-3 targeted therapy is not allowed
- Male or female patients must be ≥ 18 years of age
- Histologically or cytologically confirmed SCLC
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patients must have an archival tumor tissue available, collected within 6 months prior to screening. If an archival tumor sample, collected within 6 months prior to screening, is not available, patients must be willing to undergo a new tumor biopsy at screening; , however this specimen need not be collected prior to scheduling leukapheresis. If a new biopsy is not medically feasible, exceptions may be considered after documented discussion with the Novartis medical monitor
- Patient must be deemed suitable by the investigator to undergo the lymphodepletion (LD) regimen
- Patient must have an apheresis product of non-mobilized cells accepted for manufacturing
Who cannot take part
- Prior administration of a genetically modified cellular product, including prior DLL3- targeted CAR-T cell therapy
- History of prior solid organ transplant or allogenic hematopoietic cell transplant
- Uncontrolled seizure disorder
- Clinically significant active infections, including Hepatitis B/C and Human Immunodeficiency Virus (HIV)
- Has a known additional malignancy that is progressing or requires active treatment, with specific exceptions as defined in the study protocol
- Other significant pulmonary, cardiac, hepatic, renal or neurologic disease, parameters for which are defined in the study protocol
- Unstable or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. Stable brain metastases may participate provided they meet the specific criteria
- Pregnant or nursing women
Where in Spain
Also in 1 other country, 3 sites
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Clinico Universitario de ValenciaValencia, SpainNot yet recruiting
About the trial
What the trial wants to find out
All study parts: To characterize the safety and tolerability of DJI136 in patients with small cell lung cancer and identify the recommended dose(s) for future studies Phase II Group A: To evaluate the preliminary anti-tumor activity of DJI136
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
- Plain-language title
- Tests DJI136 cell therapy in adults with extensive-stage small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 June 2026